financetom
Business
financetom
/
Business
/
Keros Therapeutics Gets FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Treatment
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Keros Therapeutics Gets FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Treatment
Aug 20, 2025 7:34 AM

10:10 AM EDT, 08/20/2025 (MT Newswires) -- Keros Therapeutics ( KROS ) said Wednesday that KER-065 was granted orphan drug designation by the US Food and Drug Administration for the treatment of Duchenne muscular dystrophy.

Keros said it plans to advance the treatment to a phase 2 clinical trial.

Price: 14.54, Change: +0.05, Percent Change: +0.35

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved